Aurinia Pharmaceuticals (AUPH) Tops Q1 EPS by 6c ; Offers Guidance

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 EPS of $0.25, $0.06 better than the analyst estimate of $0.19. Revenue for the quarter came in at $77.7 million versus the consensus estimate of $75.29 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2026 revenue of $315-325 million, versus the consensus of $326.2 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Trump Bought At Least $100,001 In Palantir Shares, Disclosure Shows - Bloomberg
• XPeng delivers 103,295 vehicles in Q2 2026
• Tessenderlo Group to take 20% stake in FMC for $400 million